HeartSense

Heart Sense is a company creating new device for use in off-pump coronary bypass surgery for results improvement.

[HeartSense @HeartSense2]

Heart Sense is a company creating new device for use in off-pump coronary bypass surgery for results improvement and early complication risk reduction.

Visit our official website: https://t.co/7unbPDgNUq

[EACTS @EACTS]

In December 2019 the EACTS Council withdrew its support for the recommendations on left main coronary artery disease of the 2018 joint ESC-EACTS Myocardial Revascularization Guidelines.

Here we explain why: https://t.co/NyvVgAGpI8

[HeartSense @HeartSense2]

Heart Sense project web site is launched! https://t.co/hznk4drS3I
You can find information on our new technology for use in cardiac surgery. Actual information of project stages and reached milestone is given. Currently we test prototypes for best technological solutions.

[HeartSense @HeartSense2]

Moving on with Heart Sense technology. Today the project was presented on @MEDmTECH at @WSElive. Our CTO (@GreggSuwalski) and PM (Przemysław Furdal) introduced @HeartSense2 to investors, venture capital professionals, authorities and journalist.

[HeartSense @HeartSense2]

https://t.co/aTky33FzdE

[HeartSense @HeartSense2]

We will present Heart Sense idea and project flow.

[medexpress.pl @medexpresspl]

Konferencja #MEDmeetsTECH 7 listopada na @GPW_WSExchange w Warszawie

@MEDmTECH

https://t.co/SgoYVErTSZ

[HeartSense @HeartSense2]

This is very important analysis 👆If you choose stenting (PCI) against recommendations for CABG you will increase the risk of your patient 🎯 This is why with Heart Sense Device we will enforce CABG procedure!

[EJCTS_ICVTS @EACTS_Journals]

Non-compliance with recommended treatment (based on #SYNTAX score II) in #EXCEL trial, #PCI instead of #CABG, is associated with elevated 4-year mortality. By Modolo et al. #EJCTS https://t.co/Eee3djr643

[HeartSense @HeartSense2]

@theheartorg This data is a FUEL for ENGINE in our project - Heart Sense! Coronary surgery remains best option for parients with most advanced coronary artery disease! It is now needed to INCREASE safety of that procedure.

[theheartorg | Medscape @theheartorg]

SYNTAXES: CABG for best 10-year survival in multivessel disease. https://t.co/dOkJXjAvfK #ESCCongress #WCC2019 #cardiotwitter

[HeartSense @HeartSense2]

O minimalizacji ryzyka operacji serca dzięki zastosowaniu Heart Sense. https://t.co/siVd4fdO59

[HeartSense @HeartSense2]

Polacy opracowali innowacyjne urządzenie do monitorowania pracy bijącego serca https://t.co/6Xz4KDoZyL

[HeartSense @HeartSense2]

https://t.co/uYLHovapw5

[HeartSense @HeartSense2]

Heart Sense project is funded by Bridge Alfa programme (National Centre for Research and Development) and YouNick Mint (Venture Capital Fund).

[HeartSense @HeartSense2]

In following months we will inform about project progress and RnD status, show precisely the concept of the solution based on scientific data, provide information from clinical trials and epidemiological studies showing the way in which Heart Sense device may create progress.

[HeartSense @HeartSense2]

Heart Sense is company creating solution in area of heart surgery which leads to results improvement and early complication risk reduction. We have identified several key problems in current off-pump coronary artery bypass grafting (OPCAB) which limit further improvement.